Ευρωπαϊκή Ένωση -
Δανικά -
EMA (European Medicines Agency)
nitisinone mdk (previously nitisinone mendelikabs)
mendelikabs europe ltd - nitisinon - tyrosinemias - andre alimentary tract and metabolism produkter, - behandling af voksne og pædiatriske patienter (i alle aldersgrupper) med bekræftet diagnose af arvelig tyrosinæmi type 1 (ht 1) i kombination med diætbegrænsning af tyrosin og phenylalanin.
Δανία -
Δανικά -
Lægemiddelstyrelsen (Danish Medicines Agency)
nitisinone "dipharma" 5 mg kapsler, hårde
dipharma arzneimittel gmbh - nitisinon - kapsler, hårde - 5 mg
Δανία -
Δανικά -
Lægemiddelstyrelsen (Danish Medicines Agency)
nitisinone "dipharma" 2 mg kapsler, hårde
dipharma arzneimittel gmbh - nitisinon - kapsler, hårde - 2 mg
Δανία -
Δανικά -
Lægemiddelstyrelsen (Danish Medicines Agency)
nitisinone "dipharma" 10 mg kapsler, hårde
dipharma arzneimittel gmbh - nitisinon - kapsler, hårde - 10 mg
Δανία -
Δανικά -
Lægemiddelstyrelsen (Danish Medicines Agency)
nitisinone "dipharma" 20 mg kapsler, hårde
dipharma arzneimittel gmbh - nitisinon - kapsler, hårde - 20 mg
Ευρωπαϊκή Ένωση -
Δανικά -
EMA (European Medicines Agency)
nityr
cycle pharmaceuticals (europe) ltd - nitisinon - tyrosinemias - andre alimentary tract and metabolism produkter, - behandling af voksne og pædiatriske patienter med den bekræftede diagnose af arvelige tyrosinemia type 1 (ht-1) i kombination med kosten begrænsning af tyrosin og fenylalanin.
Ευρωπαϊκή Ένωση -
Δανικά -
EMA (European Medicines Agency)
orfadin
swedish orphan biovitrum international ab - nitisinon - tyrosinemias - andre alimentary tract and metabolism produkter, - hereditary tyrosinemia type 1 (ht 1)orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht 1) in combination with dietary restriction of tyrosine and phenylalanine. alkaptonuria (aku)orfadin is indicated for the treatment of adult patients with alkaptonuria (aku).
Ευρωπαϊκή Ένωση -
Δανικά -
EMA (European Medicines Agency)
skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiske og hypotalamiske hormoner og analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
Δανία -
Δανικά -
SEGES Landbrug & Fødevarer
predict flydende middel
nordisk alkali - penetreringsolie - flydende middel - 1000 g/l penetreringsolie